Intra-Cellular Therapies, Inc.

    Intra-Cellular Therapies, Inc.

    NNASDAQ:ITCI
    131.87
    USD
    0.00
    (0.00%)
    2013 Y
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    TTM
    Revenue per Share
    - -
    0.16
    0.02
    - -
    0.01
    0.01
    - -
    - -
    0.32
    1.01
    2.65
    4.82
    6.6
    6.66
    Basic EPS, GAAP
    - -
    -1.56
    -1.07
    -2.91
    -2.69
    -2.12
    -2.84
    -2.68
    -3.23
    -3.5
    -2.72
    -1.46
    -0.72
    -0.73
    Free Cash Flow per Basic Share
    - -
    -1.31
    -0.8
    -2.86
    -2.11
    -1.76
    -2.17
    -2.33
    -3.27
    -3.2
    -2.88
    -1.3
    -0.71
    -0.72
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    - -
    -3.33
    -3.08
    -5.35
    -7.16
    -8.82
    -10.28
    -12.87
    -13.32
    -15.03
    -15.71
    -16.87
    -16.4
    -16.57
    Tangible Book Value per Share
    - -
    1.83
    4.21
    13.2
    8.68
    9.84
    5.81
    3.53
    9.34
    5.14
    6.98
    6.17
    11.14
    11.25
    Basic Weighted Avg Shares
    - -
    17
    29
    36
    43
    46
    55
    55
    70
    81
    94
    96
    103
    102
    Sales/Revenue/Turnover
    - -
    3
    1
    - -
    - -
    - -
    - -
    - -
    23
    82
    249
    462
    681
    681
    Operating Margin (%)
    - -
    -959.69
    -5,659.2
    -345,131.92
    -35,759.96
    -41,732.65
    - -
    - -
    -1,026.27
    -349.65
    -105.82
    -34.48
    -17.15
    -17.15
    Depreciation Expense
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    1
    1
    1
    1
    1
    1
    Net Income, GAAP
    - -
    -27
    -31
    -105
    -116
    -98
    -155
    -148
    -227
    -284
    -256
    -140
    -75
    -75
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    - -
    -981.67
    -5,605.28
    -341,802.21
    -35,205.79
    -39,771.64
    - -
    - -
    -1,007.53
    -347.73
    -102.86
    -30.22
    -10.97
    -10.97
    Working Capital
    - -
    31
    120
    477
    378
    455
    319
    194
    654
    414
    655
    544
    1,102
    1,102
    LT Debt
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    20
    24
    19
    15
    13
    13
    13
    Total Equity
    - -
    32
    121
    476
    376
    454
    318
    195
    657
    418
    656
    591
    1,148
    1,148
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -

    Capital Structure

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    ST Debt
    4
    4
    4
    LT Borrowings
    - -
    - -
    - -
    LT Finance Leases
    14
    14
    13
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    106
    106
    106
    Market Capitalization
    6,730
    7,366
    8,529

    Working Capital

    USD

    •

    in mil. unless spec.
    Jun'24
    Sep'24
    Dec'24
    Total Current Assets
    1,264
    1,272
    1,307
    Cash, Cash Equivalents & STI
    1,023
    1,007
    1,001
    Accounts Receivable, Net
    146
    146
    167
    Inventories
    20
    24
    26
    Total Current Liabilities
    162
    166
    206
    Payables & Accruals
    135
    132
    167
    ST Debt
    4
    4
    4
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    56.8%
    68.36%
    94.19%
    Free Cash Flow
    38.51%
    0.22%
    -40.95%
    Net Income, GAAP
    26.74%
    -4.6%
    -46.54%
    Sales/Revenue/Turnover
    - -
    - -
    47.24%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    35
    55
    72
    87
    249
    2023
    95
    110
    126
    132
    462
    2024
    145
    161
    175
    199
    681

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    -0.78
    -0.92
    -0.57
    -0.46
    -2.72
    2023
    -0.46
    -0.45
    -0.25
    -0.3
    -1.46
    2024
    -0.16
    -0.16
    -0.25
    - -
    -0.72

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2022
    - -
    - -
    - -
    - -
    - -
    2023
    - -
    - -
    - -
    - -
    - -
    2024
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business

    Company News

    Company News APIChatGPT

    • globenewswire.com

      Phathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

    • businesswire.com

      INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

    • businesswire.com

      ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders

    • zacks.com

      ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales

    • zacks.com

      Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates

    • globenewswire.com

      Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results

    • cnbc.com

      Healthy Returns: Biotech and pharma M&A is off to a good start in 2025 — but will it last?

    • prnewswire.com

      SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ENFN and ITCI on Behalf of Shareholders

    • zacks.com

      Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer

    • zacks.com

      Intra-Cellular (ITCI) Moves 34.1% Higher: Will This Strength Last?

    • businesswire.com

      INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI

    • businesswire.com

      Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

    • https://thefly.com

      BofA moves to No Rating on Intra-Cellular after Johnson & Johnson deal

    • zacks.com

      ITCI Stock Rises 15% on Settling Caplyta Patent Litigation With Sandoz

    • reuters.com

      Drugmakers rush to sign deals on first day of industry conference

    • https://thefly.com

      Intra-Cellular just downgraded at Morgan Stanley, here's why

    • investopedia.com

      Intra-Cellular Therapies Stock Pops as Johnson & Johnson Buys Firm for $14.6B

    • businesswire.com

      ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-Cellular Therapies, Inc. Is Fair to Shareholders

    • zacks.com

      Intra-Cellular (ITCI) Surges 14.9%: Is This an Indication of Further Gains?

    • reuters.com

      J&J to buy Intra-Cellular Therapies for $14.6 billion